The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis.
Liza RijversMarie-José MeliefRoos M van der Vuurst de VriesMaeva StéphantJamie van LangelaarAnnet F Wierenga-WolfJeanet M HogervorstAnneke J Geurts-MoespotFred C G J SweepRogier Q HintzenMarvin M van LuijnPublished in: European journal of immunology (2018)
In MS, B cells survive peripheral tolerance checkpoints to mediate local inflammation, but the underlying molecular mechanisms are relatively underexplored. In mice, the MIF pathway controls B-cell development and the induction of EAE. Here, we found that MIF and MIF receptor CD74 are downregulated, while MIF receptor CXCR4 is upregulated in B cells from early onset MS patients. B cells were identified as the main immune subset in blood expressing MIF. Blocking of MIF and CD74 signaling in B cells triggered CXCR4 expression, and vice versa, with separate effects on their proinflammatory activity, proliferation, and sensitivity to Fas-mediated apoptosis. This study reveals a new reciprocal negative regulation loop between CD74 and CXCR4 in human B cells. The disturbance of this loop during MS onset provides further insights into how pathogenic B cells survive peripheral tolerance checkpoints to mediate disease activity in MS.
Keyphrases
- multiple sclerosis
- early onset
- mass spectrometry
- disease activity
- ms ms
- endothelial cells
- systemic lupus erythematosus
- rheumatoid arthritis
- end stage renal disease
- late onset
- ejection fraction
- white matter
- rheumatoid arthritis patients
- chronic kidney disease
- oxidative stress
- newly diagnosed
- ankylosing spondylitis
- transcription factor
- nk cells
- prognostic factors
- binding protein
- pluripotent stem cells
- signaling pathway
- adipose tissue
- type diabetes
- patient reported outcomes
- high fat diet induced
- metabolic syndrome